Page 138 - 《中国药房》2023年18期

Role of spinal mu opioid receptors in the development of [34] DONG Y X，CHANG X H. Comparison of five prophylac‐
morphine tolerance and dependence[J]. J Pharmacol Exp tically intravenous drugs in preventing opioid-induced
Ther，1984，231（1）：91-96. cough：a Bayesian network meta-analysis of randomized
[21] INAN S，TORRES-HUERTA A，JENSEN L E，et al. Nal‐ controlled trials[J]. Front Pharmacol，2021，12：684276.
buphine，a kappa opioid receptor agonist and mu opioid [35] WANG X J，CHEN Y，WANG Z F，et al. Effect of dezo‐
receptor antagonist attenuates pruritus，decreases IL-31， cine on hemodynamic indexes of postoperative patients
and increases IL-10 in mice with contact dermatitis[J]. with traumatic brain injury（TBI）：a pilot study[J]. Front
Eur J Pharmacol，2019，864：172702. Pharmacol，2022，13：665107.
[22] RUAN D J，WANG Y Y，LI S S，et al. Nalbuphine [36] FERRACANE M J，BRICE-TUTT A C，COLEMAN J S，
alleviates inflammation by down-regulating NF-κB in an et al. Design，synthesis，and characterization of the macro‐
acute inflammatory visceral pain rat model[J]. BMC cyclic tetrapeptide cyclo[pro-sar-phe-d-phe]：a mixed
Pharmacol Toxicol，2022，23（1）：34. opioid receptor agonist-antagonist following oral admini-
[23] LEE S C，WANG J J，HO S T，et al. Nalbuphine coad- stration[J]. ACS Chem Neurosci，2020，11（9）：1324-1336.
ministered with morphine prevents tolerance and depen‐ [37] KIM E S. Oxycodone/naloxone prolonged release：a
dence[J]. Anesth Analg，1997，84（4）：810-815. review in severe chronic pain[J]. Clin Drug Investig，
[24] IBRAHIM A M，OBAIDI Z，RUAN G，et al. Nalbuphine 2017，37（12）：1191-1201.
for opioid-induced urine retention[J]. Ann Intern Med， [38] DUPOIRON D，STACHOWIAK A，LOEWENSTEIN O，
2023，169（12）：894-895. et al. A phase Ⅲ randomized controlled study on the effi‐
[25] INFANTINO R，MATTIA C，LOCARINI P，et al. cacy and improved bowel function of prolonged-release
（PR）oxycodone-naloxone（up to 160/80 mg daily）vs oxy‐
Buprenorphine：far beyond the “ceiling”[J]. Biomolecules，
codone PR[J]. Eur J Pain，2017，21（9）：1528-1537.
2021，11（6）：816.
[39] CHEN X T，PITIS P，LIU G D，et al. Structure-activity
[26] COE M A，LOFWALL M R，WALSH S L. Buprenorphine
pharmacology review：update on transmucosal and long- relationships and discovery of a G protein biased μ opioid
receptor ligand，[（3-methoxythiophen-2-yl）methyl]（{2-
acting formulations[J]. J Addict Med，2019，13（2）：
[ （9R） -9- （pyridin-2-yl） -6-oxaspiro- [4.5]decan-9-yl]
93-103.
ethyl}）amine（TRV130），for the treatment of acute severe
[27] SHULMAN M，WAI J M，NUNES E V. Buprenorphine
pain[J]. J Med Chem，2013，56（20）：8019-8031.
treatment for opioid use disorder：an overview[J]. CNS
[40] DEUIS J R，DVORAKOVA L S，VETTER I. Methods
Drugs，2019，33（6）：567-580.
used to evaluate pain behaviors in rodents[J]. Front Mol
[28] MADISON C A，EITAN S. Buprenorphine：prospective
Neurosci，2017，10：284.
novel therapy for depression and PTSD[J]. Psychol Med，
[41] AKGÜN E，LUNZER M M，TIAN D F，et al. FBNTI，a
2020，50（6）：881-893.
DOR-selective antagonist that allosterically activates
[29] ZHU F，DUAN W，ZHONG C，et al. The protective effects
MOR within a MOR-DOR heteromer[J]. Biochemistry，
of dezocine on interleukin-1β -induced inflammation，
2021，60（18）：1413-1419.
oxidative stress and apoptosis of human nucleus pulposus
[42] OLSON K M，HILLHOUSE T M，BURGESS G E，et al.
cells and the possible mechanisms[J]. Bioengineered， Delta opioid receptor-mediated antidepressant-like effects
2022，13（1）：1399-1410. of diprenorphine in mice[J]. J Pharmacol Exp Ther，2023，
[30] WU F X，BABAZADA H，GAO H，et al. Dezocine
384（3）：343-352.
alleviates morphine-induced dependence in rats[J].
[43] IMAM M Z，KUO A，GHASSABIAN S，et al. Intracere‐
Anesth Analg，2019，128（6）：1328-1335.
broventricular administration of CYX-6，a potent μ-opioid
[31] YU F，ZHOU J，XIA S Y，et al. Dezocine prevents posto- receptor agonist，a δ- and κ-opioid receptor antagonist and
perative hyperalgesia in patients undergoing open abdomi‐ a biased ligand at μ，δ & κ-opioid receptors，evokes anti‐
nal surgery[J]. Evid Based Complement Alternat Med， nociception with minimal constipation and respiratory
2015，2015：946194. depression in rats in contrast to morphine[J]. Eur J Phar‐
[32] AHSAN M Z，ZHAO M J，SHOAIB R M，et al. Compara‐ macol，2020，871：172918.
tive study of dezocine，pentazocine and tapentadol on anti‐ [44] SUN J F，WANG Y H，CHAI J R，et al. Pharmacological
nociception and physical dependence[J]. Life Sci，2021， characterization and therapeutic potential for the treatment
285：119996. of opioid abuse with ATPM-ET，an N-ethyl substituted
[33] ZHAO P，WU Z X，LI C R，et al. Postoperative analgesia aminothiazolomorphinan with κ agonist and μ agonist/an‐
using dezocine alleviates depressive symptoms after tagonist activity[J]. Eur J Pharmacol，2014，740：455-463.
colorectal cancer surgery：a randomized，controlled， （收稿日期：2023-05-31 修回日期：2023-08-16）
double-blind trial[J]. PLoS One，2020，15（5）：e0233412. （编辑：孙 冰）

· 2304 · China Pharmacy 2023 Vol. 34 No. 18 中国药房 2023年第34卷第18期